Transformation, quantified.
Anonymized engagements illustrating how Tailomere's approach translates into shipped production AI and measurable business outcomes.
Placeholder content — to be replaced with real engagements before launch.
From GenAI experiments to a governed deployment pipeline in 90 days.
Executive pressure to "do AI" had produced six disconnected pilots, zero in production, and rising regulatory concern.
Readiness Assessment followed by a Fractional CAIO engagement. Introduced a central governance council, a use-case portfolio, and a production deployment gate.
- Two pilots promoted to production within 90 days.
- 40% reduction in vendor redundancy across AI tooling.
- Board-level risk posture upgraded from amber to green.
Agentic AI roadmap that satisfies clinical compliance and sales pressure.
Sales-driven AI feature commitments were outpacing the compliance and safety review process.
Executive workshop plus an AI Sprint to define a staged roadmap, model selection framework, and a HIPAA-aligned deployment pattern.
- Unified 12 feature requests into 3 prioritized agentic workflows.
- Reduced pre-sales AI-question turnaround from 10 days to 24 hours.
- Shipped first compliant agentic feature to design-partner customers.
A build-vs-buy decision that saved an estimated $1.8M in 18 months.
Internal team was six months into building a custom LLM stack with unclear differentiation.
Two-week Readiness Assessment and build-vs-buy evaluation. Recommended vendor consolidation on a frontier model with fine-tuning on proprietary data.
- Retired internal model infrastructure; redeployed engineers to integration work.
- Cut monthly run cost by 62% versus projected self-hosted path.
- Time-to-first-production use case reduced from 9 months to 11 weeks.